Thymidylate synthase inhibitors are chemical agents which inhibit the enzyme Thymidylate synthase and have potential as an anticancer chemotherapy.[1]
Examples
In 2002 five were in clinical trials: raltitrexed, pemetrexed, nolatrexed, ZD9331, and GS7904L.[2]
Examples include
- Raltitrexed used for colorectal cancer since 1998
- fluorouracil used for colorectal cancer[3]
- BGC 945 [4]
References
- ^ "Folate-based thymidylate synthase inhibitors as anticancer drugs -- Jackman and Calvert 6 (9): 871 -- Annals of Oncology". http://annonc.oxfordjournals.org/cgi/content/abstract/6/9/871+. Retrieved on 2009-01-28.
- ^ "Thymidylate synthase inhibitors as anticancer agents: from bench to bedside". http://cat.inist.fr/?aModele=afficheN&cpsidt=15072905+. Retrieved on 2009-01-28.
- ^ Papamichael D (1999). "The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status". Oncologist 4 (6): 478–87. PMID 10631692. http://theoncologist.alphamedpress.org/cgi/pmidlookup?view=long&pmid=10631692.
- ^ "BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to {alpha}-Folate Receptor-Overexpressing Tumors -- Gibbs et al. 65 (24): 11721 -- Cancer Research". http://cancerres.aacrjournals.org/cgi/content/abstract/65/24/11721+. Retrieved on 2009-01-28.
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
